Sapient Capital’s Moderna MRNA Stock Holding History

Sapient Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,288	Closed	-$319K	–	454
2026 Q1	$319K	Buy	+6,288	New	+$293K	﹤0.01%	346

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Sapient Capital's MRNA Position: Q2 2026 in Review

Sapient Capital sold out of Moderna (MRNA) in Q2 2026, closing a stake of 6,288 shares — an estimated $319K sold.

Sapient Capital first reported a position in MRNA in Q1 2026 and held it in 1 quarter. The position peaked at $319K in Q1 2026. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Sapient Capital reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Sapient Capital sold 6,288 Moderna shares in Q2 2026, an estimated $319K.
Sapient Capital first reported a position in Moderna in Q1 2026 and held it in 1 quarter.
Sapient Capital's Moderna position peaked at $319K in Q1 2026.
775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Sapient Capital's 13F filing for Q2 2026, filed 9 Jul 2026.